Track topics on Twitter Track topics that are important to you
Voltavägen 13,floor 5
Phone: 46 (0) 8 598 838 00
Fax: 46 (0) 8 598 838 01
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. During NLSD in...
NewsIn a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2-expressing cancers is non-toxic to the kidneys and improves survival.
SummaryAffibody AB Affibody is a biotech company that develops next generation biopharmaceuticals. The company develops drugs based on its proprietary technology platforms such as Affibody molecules a...
(Society of Nuclear Medicine and Molecular Imaging) In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth facto...
Development of new affinity proteins using combinatorial protein engineering is today established for generation of monoclonal antibodies and also essential for discovery of binders that are based on ...
Affibody molecules are small proteins engineered using a non-antibody scaffold. Radiolabeled affibody molecules are excellent imaging probes, but their application for radionuclide therapy was so far ...
Human epidermal growth factor receptor type 3 (HER3) is recognized to be involved in resistance to HER-targeting therapies. A number of HER3-targeting monoclonal antibodies are under clinical investig...
Patients with HER2-positive tumors often suffer resistance to therapy, warranting development of novel treatment modalities. Affibody molecules, which are small affinity proteins which can be engineer...
The selective detection of specific cells of interest and their effective visualization is important but challenging, and fluorescent cell imaging with target-specific probes is commonly used to visua...
The investigators developed [68Ga]-labelling Anti-IGF-1R Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting IGF-1R expression status.
The investigators developed [68Ga]-labelling Anti-EGFR Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-ECD expression status.
This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study to investigate the diagnostic performance and evaluation efficacy of 99mTc-ABH2 in breast cance...
A large multi- center phase II/III study with 68Ga-ABY-025 PET and biopsies in patients with advanced HER2-positive breast cancer, where the primary endpoint of the study is to find out th...
Affibody has developed a unique pipeline of affinity ligands in oncology, covering the entire value chain from research reagents to molecular imaging agents and targeted therapeutics. The company has ...
We have published hundreds of Affibody news stories on BioPortfolio along with dozens of Affibody Clinical Trials and PubMed Articles about Affibody for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Affibody Companies in our database. You can also find out about relevant Affibody Drugs and Medications on this site too.
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...